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Abstract
Background: C-reactive protein (CRP), a marker of systemic inflammation, is associated with risk of coronary events and sub-
clinical measures of atherosclerosis. Evidence in support of this link being causal would include an association robust to
adjustments for confounders (multivariable standard regression analysis) and the association of CRP gene polymorphisms
with atherosclerosis (Mendelian randomization analysis).
Methodology/Principal Findings: We genotyped 3 tag single nucleotide polymorphisms (SNPs) [+1444T.C (rs1130864);
+2303G.A (rs1205) and +4899T.G (rs 3093077)] in the CRP gene and assessed CRP and carotid intima-media thickness
(CIMT), a structural marker of atherosclerosis, in 4941 men and women aged 50–74 (mean 61) years (the Whitehall II Study).
The 4 major haplotypes from the SNPs were consistently associated with CRP level, but not with other risk factors that might
confound the association between CRP and CIMT. CRP, assessed both at mean age 49 and at mean age 61, was associated
both with CIMT in age and sex adjusted standard regression analyses and with potential confounding factors. However, the
association of CRP with CIMT attenuated to the null with adjustment for confounding factors in both prospective and cross-
sectional analyses. When examined using genetic variants as the instrument for serum CRP, there was no inferred
association between CRP and CIMT.
Conclusions/Significance: Both multivariable standard regression analysis and Mendelian randomization analysis suggest
that the association of CRP with carotid atheroma indexed by CIMT may not be causal.
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Introduction
C-reactive protein (CRP) is a non-specific marker of systemic
inflammation, but whether it plays a causal role in atherosclerosis
and its complications remains controversial. Findings examining
potential direct proatherogenic effects of CRP in vitro and in vivo
are mixed [1–3]. Randomised controlled trials specific to CRP are
currently lacking. Several observational studies show high
circulating CRP to be associated with increased risk of coronary
heart disease (CHD) events [4–6] and increased carotid intima-
media thickness (CIMT) [7–9], a subclinical marker of athero-
sclerosis [10,11]. However, these associations may have non-causal
explanations as a result of reverse causality (i.e., CRP levels may be
altered as a result of atherosclerosis rather than being a cause of it)
or confounding (the association of CRP with atherosclerosis may
arise from the common association of the two with other causative
factors). Indeed, CRP is related to many other risk factors, such as
obesity, smoking and socioeconomic adversity, as well as other
‘‘novel’’ risk factors such as fibrinogen and interleukin-6 [7,12–14].
Recent genetic findings offer opportunities for testing the causal
relevance of CRP using the principles of Mendelian randomization
[15–18]. Common genetic variants have been identified that robustly
affect the level of circulating CRP [19–21]. Because of their
randomized allocation at conception (according to Mendel’s Laws),
the genetic variants may be used as unconfounded proxies for CRP.
The ‘‘central dogma’’ of the unidirectional flow of information from
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common genome variation R protein R phenotype over the life
course also means that reverse causality and effect dilution are
overcome in genetic studies. Thus, use of gene variants as an
unconfounded instrument for CRP levels offers the opportunity of
assessing the causal relevance of CRP for atherosclerosis.
To our knowledge two previous studies have examined the
association of genetic variants in the CRP gene with CIMT. The
Cardiovascular Risk Factors in Young Finns study used variation
in the CRP haplotypes as an instrument for unconfounded CRP
levels and found no association between the CRP instrument and
CIMT in young adults aged 24 to 39 years [22]. However, CIMT
may not be as appropriate an indicator of atherosclerosis in that
age group as in older people [23]. In the US population-based
Cardiovascular Health Study, conducted on older adults, there
was also no direct associations between CRP haplotypes and
CIMT although an association of CRP single nucleotide
polymorphisms (SNPs) with CHD events was noted in a subgroup
[24]. However, the study did not directly evaluate the quantititive
associations of CRP genotypes, CRP and vascular outcomes for
their consistency. An instrumental variables analysis using CRP
genotypes or haplotypes as a proxy for CRP would inform whether
CRP levels are causally associated with CIMT [16].
We sought to investigate the potential for a causal association
between CRP and atherosclerosis by standard observational
methods of multivariable analyses, adjusting for confounding by
other risk factors, and also by using haplotypes from 3 variants in
the CRP gene as instrumental variables for the unconfounded and
unbiased (by reverse causation and regression dilution bias) effect
of CRP on CIMT. Analyses were undertaken in a well-established
occupational cohort of British civil servants, the Whitehall II study,
who were at mean age 49 at the first measurement of CRP and at
61 at the second measurement of CRP. In a companion paper
based on Whitehall II and four other cohorts we extend the
instrumental variables analysis to disease endpoints by examining
the associations between CRP genotype, circulating CRP and
manifest CHD [25].
Results
Participants were mostly men and from non-manual position as
the latest occupational status (table 1). As expected, CRP
haplotypes were associated with circulating CRP levels (table 2)
explaining in combination 3.9% of the variation in CRP at age
49 years and 3.3% of the variation in CRP at age 61 years. CRP
haplotypes were not, however, associated with risk factors, such as
high blood pressure, dyslipidaemia, obesity, physical inactivity and
low socioeconomic position (1 of 36 tests statistically significant at
p,0.05; 1–2 would have been expected by chance). In contrast, all
of the risk factors were associated with serum CRP and/or CIMT
(table 3).
After adjustment for age and sex, higher contemporaneous and
previous serum CRP concentrations were associated with
increased CIMT (table 4). However, further adjustment for risk
factors attenuated these associations to the null suggesting that risk
factors may confound or mediate the association between CRP
and CIMT. The total reduction of the magnitude of the CRP-
CIMT association between the two models at the mean age of 61.0
was 75%. Of the separate risk factors, adjustment for BMI alone
reduced the age- and sex-adjusted association between CRP and
CIMT by 57% (p for association = 0.16 after adjustment), the
corresponding reduction being 29% for systolic blood pressure,
27% for HDL-cholesterol and less than 15% for other risk factors
(p,= 0.01). Excluding those with CRP greater than 10 mg/L
(n = 54 at age 49.2; n = 105 at age 61.0) had little effect on the
results presented in table 4. The findings were also replicated in a
subcohort including only individuals with no CHD or diabetes
(n = 2608 for CRP measured at mean age 61, n = 2393 for CRP at
mean age 49).
The analysis of haplotypes in the CRP gene as instrumental
variables for the unconfounded and unbiased effect of CRP on
CIMT, was undertaken using two-stage least squares method [16].
All F-statistics from the first-stage regressions in the instrumental
variable models were greater than 10 (17.4 for contemporaneous
Table 1. Participant Characteristics.
Characteristic Mean (SD) N (%) Median (IQR) Total N
Age, y 61.0 (6.0) 4941
Women 1331 (26.9) 4941
Systolic blood pressure, mm Hg 127 (17) 4939
Diastolic blood pressure, mm Hg 74 (10) 4939
HDL cholesterol, mmol/l 1.58 (0.45) 4939
LDL cholesterol, mmol/l 3.51 (1.75) 4883
Triglycerides, mmol/l 1.39 (0.92) 4939
Body mass index, kg/m2 26.7 (4.2) 4920
Physical inactivity 738 (15.1) 4886
Low occupational status* 400 (8.2) 4903
Ever smoking 2369 (48.0) 4938
Prevalent diabetes 329 (7.2) 4583
Prevalent coronary heart disease 410 (8.3) 4941
Serum C-reactive protein, mg/L 1.22 (0.63–2.59) 4941
Previous serum C-reactive protein, mg/L{ 0.83 (0.42–1.69) 4435
Carotid intima-media thickness, mm 0.79 (0.15) 3299
*Low occupational status refers to clerical position in a three level hierarchy of administrative, professional and clerical employment grade.
{Measured at mean age of 49.2 (SD = 6.0) years
doi:10.1371/journal.pone.0003013.t001
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and 16.8 for previous serum CRP) indicating sufficient strength to
ensure the validity of instrumental variable methods in these data.
The second step of the instrumental variables analysis, consistent
with the confounder adjusted standard regression analysis,
suggested no association between CRP and CIMT, though this
was estimated with wide confidence intervals (table 5). This finding
was replicated in a subcohort that included only individuals with
no CHD or diabetes (for contemporaneous association at mean
age 61 age- and sex-adjusted beta =20.007, 95% CI 20.039 to
0.25, p = 0.68, N = 2660; the corresponding figures where
beta =20.006, 95% CI 20.039 to 0.027, p = 0.72, N = 2440 for
CRP measured at mean age 49 and CIMT at mean age 61).
Finally, levels of CIMT did not vary by CRP haplotypes (all
p.0.63) suggesting that these haplotypes have no effect on CIMT
although they are consistently associated with serum CRP
concentrations in middle and late adulthood in this cohort.
Discussion
Atheromatous plaques start to progress from childhood and
may eventually become prone to plaque rupture in adulthood
leading to clinical events, such as acute myocardial infarction,
unstable angina or stroke. In this large prospective cohort study,
both a Mendelian randomization approach, in which confounding
is controlled for by using genetic variants as instruments for the
unconfounded association, and standard multivariable regression
analyses (adjusting for a range of potential confounding factors)
were consistent in showing no independent association of CRP
with CIMT. These findings could be explained if CRP does not
itself contribute to the development of atherosclerosis but rather
marks pro-atherogenic exposures, the presence of atheroma, or a
combination of the two.
We used haplotypes in the CRP gene that were constructed on
the basis of tag SNPs rs1205, rs1130864 and rs3093077 that
capture comprehensively the common variability at the CRP locus
in subjects of European descent [19–21]. A recent large-scale
meta-analysis of genetic association studies of 8 CRP polymor-
phisms and CRP concentration used a novel Bayesian approach
that allows integration of informative data from a wide range of
studies, irrespective of the specific CRP polymorphism typed [26].
All the three SNPs we studied were found to mark haplotypes
likely to harbour functional variants in the vicinity of the CRP gene
that could regulate its level. In the present study, these SNPs were
consistently associated with serum CRP levels across two time
points 12 years apart suggesting that the haplotypes defined
groups with long-term differences in circulating CRP. However,
there was no strong statistical evidence that these haplotypes
Table 2. Association Between 4 CRP Haplotypes and Serum
C-reactive Protein (CRP) Concentration.
Median (IQR) CRP, mg/L
Haplotype of +1444, +2302
and +4899 SNPs
At mean age
61.0 years
(n =4941)
At mean age
49.2 years
(n=4435)
CAT
0 (n = 2165 at age 61.0/n = 1955
at mean age 49.2)
1.34 (0.72 to 2.75) 0.91 (0.46 to 1.91)
1 (n = 2249/2008) 1.17 (0.61 to 2.50) 0.78 (0.39 to 1.58)
2 (n = 527/472) 1.00 (0.48 to 2.06) 0.73 (0.37 to 1.36)
P for trend* ,0.0001 ,0.0001
CGG
0 (n = 4423/3971) 1.18 (0.62 to 2.51) 0.80 (0.41 to 1.65)
1 (n = 499/447) 1.50 (0.81 to 2.97) 0.98 (0.56 to 1.93)
2 (n = 19/17) 1.97 (1.13 to 4.67) 1.82 (1.47 to 4.36)
P for trend* ,0.0001 ,0.0001
CGT
0 (n = 2383/2126) 1.25 (0.64 to 2.66) 0.87 (0.44 to 1.80)
1 (n = 2101/1901) 1.19 (0.63 to 2.47) 0.78 (0.40 to 1.62)
2 (n = 457/408) 1.21 (0.69 to 2.69) 0.80 (0.40 to 1.68)
P for trend* 0.74 0.006
TGT
0 (n = 2333/2091) 1.15 (0.59 to 2.45) 0.78 (0.39 to 1.56)
1 (n = 2189/1968) 1.26 (0.66 to 2.63) 0.84 (0.43 to 1.76)
2 (n = 419/376) 1.50 (0.76 to 2.86) 1.03 (0.55 to 2.45)
P for trend* ,0.0001 ,0.0001
*Adjusted for age and sex.
doi:10.1371/journal.pone.0003013.t002
Table 3. Contemporaneous Associations of Risk Factors with Serum C-reactive Protein (CRP) Concentration and Carotid Intima-
media Thickness (CIMT) at Mean Age 61.0 Years*.
Log CRP (mg/L) CIMT (mm)
Risk factor N Beta (95% CI) P N Beta (95% CI) P
Systolic blood pressure, mm Hg 4939 0.009 (0.007 to 0.011) ,0.0001 3299 0.001 (0.001 to 0.002) ,0.0001
Diastolic blood pressure, mm Hg 4939 0.017 (0.015 to 0.021) ,0.0001 3299 0.001 (0.000 to 0.001) 0.002
HDL-cholesterol, mmol/l 4939 20.64 (20.71 to 20.57) ,0.0001 3299 20.027 (20.039 to 20.015) ,0.0001
LDL-cholesterol, mmol/l 4883 0.016 (20.001 to 0.033) 0.07 3266 0.003 (0.001 to 0.006) 0.008
Triglycerides, mmol/l 4939 0.21 (0.17 to 0.24) ,0.0001 3299 0.005 (20.001 to 0.011) 0.10
Body mass index, kg/m2 4920 0.10 (0.096 to 0.11) ,0.0001 3291 0.003 (0.002 to 0.005) ,0.0001
Smoking{ 4938 0.22 (0.16 to 0.28) ,0.0001 3297 0.019 (0.009 to 0.029) 0.0003
Physical inactivity{ 4886 0.18 (0.10 to 0.27) ,0.0001 3274 0.000 (20.014 to 0.015) 0.96
Low occupational status{ 4903 0.16 (0.04 to 0.27) 0.009 3282 0.001 (20.019 to 0.022) 0.90
*Based on age- and sex-adjusted linear regression models.
{Binary variables: 0 = never smoker, 1 = ever smoker; 0 = non-sedentary, 1 = sedentary; 0 = non-manual, 1 =manual.
doi:10.1371/journal.pone.0003013.t003
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influencing serum CRP levels were related to CIMT after taking
into account the magnitude of their association with CRP. This
null finding is assumed to represent a non-confounded and
unbiased estimate of the association between CRP and CIMT
because the existence of early stages of atherosclerosis cannot alter
inherited haplotypes [15], and the potential confounders of the
CRP-atherosclerosis association (e.g., obesity, smoking, physical
inactivity or socioeconomic adversity) were distributed evenly
among the different CRP haplotypes.
Our findings are consistent with the null findings in two smaller
studies on CRP genotypes and CIMT, one related to young adults
aged 24 to 39 years [22] and the other to an older cohort than
ours [24]. In combination, these and other genetic studies related
to less direct correlates of atherosclerosis, such as blood pressure
[12] and metabolic syndrome [20] provide evidence against the
status of CRP as a causal factor for atherosclerosis. Lange et al.
[24] suggest that CRP may affect plaque rupture rather than
atherosclerosis in a study reporting an association of CRP genotype
with incident CHD in a subgroup but no association with CIMT
in the same subgroup or in the study population as a whole.
However, the association between CRP genotype and CHD has
not been confirmed by other studies or meta-analyses [19,25,27].
A companion for this study is the largest meta-analysis on this issue
to date, based on Whitehall II and four other general population
cohorts. That study showed no association between a single CRP
polymorphism and incident or prevalent CHD in a total of 18,637
participants (4,610 cases) [25]. However, a very large sample size
(around 20,000 cases and controls), with comprehensive tag SNP
typing, such as that being assembled by the CRP-CHD genetics
collaboration (CCGC) [28], will be necessary to confirm or refute
a causal association of CRP with risk of CHD events.
Several issues may compromise the value of the Mendelian
randomisation approach in determining causality [29]. First, such
an approach requires the existence of genetic variants that have
been shown to be robustly (replicated in several independent
studies) associated with the non-genetic modifiable exposure of
interest. For the haplotypes that we have used here, such a robust
association has been established in multiple independent studies
[20,21,30–38], and was confirmed in our dataset. Furthermore,
the association of the haplotype (instrumental variable) was strong
enough for the instrumental variables analysis to be consistent as
the F-statistic was above the value of 10 suggested as a threshold to
distinguish weak vs. strong instruments [39].
Second, population stratification, resulting from factors such as
ancestral patterns of geographical migration and differences in
mating practices and reproductive behaviors between populations,
may confound genotype-phenotype associations and is often
speculated to be the reason for non-replication of genetic
associations [40]. There is some evidence of such confounding in
relation to ethnic groups, i.e., relationships between genotype and
phenotype that were found in multiethnic populations disappeared
when analysed separately in each ethnic group [41,42]. Population
stratification may not only potentially lead to such false positive
genotype-phenotype associations but can also, in principle, mask
associations. To increase protection against bias from population
stratification we restricted our analyses on white Europeans only.
We also confirmed that there was no stratification in CRP
haplotypes between socioeconomic groups. Furthermore, the null
finding of CRP haplotype and CIMT is replicable as consistent
findings have been obtained from this UK study and studies in a
US and Finnish population [22,24]. For these reasons, it seems
unlikely that population stratification would have masked a causal
association between CRP and CIMT.
Third, the Mendelian randomisation approach may be
compromised if genetic variants used as instruments have multiple
effects on phenotype (pleiotropy) or if the variants are in linkage
disequilibrium with another genetic variant, that influences the
pathway of interest in the opposite direction. We think pleiotropy
is unlikely for the variants that we used to generate the CRP
haplotypes as they are in very close linkage disequilibrium with
variation within a putative transcription factor binding site located
59 of the CRP gene that has been associated with circulating
concentrations of CRP and thought to be functional [43,44]. The
variants also lie in a block of allelic association that does not
contain any other gene with a role in CRP regulation [26,45].
Fourth, developmental compensation (or canalization) in early
life whereby genetically-determined alterations in CRP might be
buffered by compensatory changes in other systems may
Table 4. Associations Between Serum C-reactive Protein (CRP) Measured at Two Time Points and Carotid Intima-media Thickness
(CIMT) Obtained from Standard Multivariable Regression Analysis.
Beta (95% CI) for CIMT (mm) at mean age 61.1
Exposure N Age and sex adjusted Age, sex and risk factor adjusted*
Per doubling of CRP concentration at mean age of 61.0 years 3225 0.006 (0.003 to 0.009) P= 0.0004 0.001 (20.002 to 0.005) P = 0.41
Per doubling of CRP concentration at mean age 49.2 years 2948 0.006 (0.002 to 0.009) P= 0.0006 0.001 (20.002 to 0.005) P = 0.30
Only participants with no missing data in any of the covariates are included.
*Adjusted for age, sex, systolic blood pressure, diastolic blood pressure, HDL-cholesterol, LDL-cholesterol, triglycerides, body mass index, smoking, physical inactivity,
and low occupational status.
doi:10.1371/journal.pone.0003013.t004
Table 5. Associations of C-reactive Protein (CRP) with Carotid Intima-media Thickness (CIMT) Obtained from the Instrumental
Variables Analysis in Which CRP Haplotypes Act as An Instrument for the Non-confounded and Unbiased Effect of CRP.
Exposure N
Age and Sex Adjusted Beta (95% CI) for CIMT (mm)
at Mean Age of 61.0 Years
Per doubling of CRP concentration at mean age 61.0 3299 20.005 (20.031 to 0.021) P = 0.71
Per doubling of CRP concentration at mean age 49.2 3016 20.001 (20.025 to 0.023) P = 0.94
doi:10.1371/journal.pone.0003013.t005
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compromise the validity of the Mendelian randomisation ap-
proach [46]. However, most recognised examples of developmen-
tal compensation relate to dramatic genetic or environmental
insults [46] and it is unclear whether the generally smaller
phenotypic differences induced by common functional polymor-
phisms, as used in our study, will be sufficient to induce
compensatory responses.
Fifth, the most important limitation is that the instrumental
variables analysis provided wide confidence intervals for the effects
of CRP on CIMT suggesting that larger samples are needed to
obtain more precise estimation. Moreover, CIMT, although a
valid non-invasive index of carotid atherosclerosis [11], may not
comprehensively capture the general atherosclerotic process.
Nevertheless, despite these limitations, standard multivariable
regression analyses of CRP levels and CIMT produced converging
support for the conclusions from Mendelian randomization
analyses. The association between serum CRP and CIMT
attenuated towards the null in adjustments for obesity and other
risk factors and this is consistent with several previous studies [7–
9,47]. It has been argued that systemic inflammation (of which
CRP is a marker) might cause increases in blood pressure, BMI
and changes in lipid profiles that might mediate an increase in
CIMT and CHD risk [48]. If so, adjustment for these variables in
a multivariable model might actually be controlling for factors in
the causal pathway. However, adjustment for BMI (which had the
most potent attenuating effect) is unlikely to represent an
overadjustment, since weight gain is associated with an increase
in CRP, and weight loss with a CRP reduction [49–51].
Furthermore, CRP genotypes that are associated with higher
CRP were not associated with BMI, nor with a range of other
established or novel risk factors for CHD [19,20,22].
In conclusion, the consistency of evidence from both the
Mendelian randomisation approach and the multivariable regres-
sion analysis approach (each of which has distinct, but differing
potential limitations) implies that the association of CRP with
CIMT may be better explained by CRP marking the presence of
atheroma, or other risk factors rather than having a direct causal
role itself, as has been suggested [52]. However, much larger
analyses using the genetic approach we and others have described,
as well as intervention studies involving a new, specific CRP-
inhibitor [53] are needed to more definitively assess the potential
causal role for CRP in atherosclerosis and CHD.
Materials and Methods
Participants
In 1985, all non-industrial civil servants aged between 35 and
55, in 20 departments in Central London were invited to a
cardiovascular medical examination at their workplace [54]. With
a 73% participation, the cohort included 6895 men and 3413
women at study entry in 1985–1988. Measurement of CRP was
conducted in 1991–1993 and again in 2003–2004 when variants
in the CRP gene were genotyped and CIMT was assessed. A total
of 5949 individuals participated in the latter clinical screening and
were successfully genotyped for variants in the CRP gene. We
excluded non-white subjects (n = 481), those with missing data on
haplotypes (n = 13) or CRP concentration (n = 514). Thus, the
study sample with complete data on CRP genotype and CRP
levels for the cross-sectional analyses in 2003–2004 included 4941
(3610 men and 1331 women) individuals aged 50–74 years (mean
age 61.0). We additionally performed prospective analyses with
CRP in 1991–1993 as the exposure variable. For these analyses,
the study sample comprised 4435 (3255 men and 1180 women)
individuals, a sub-group of those included in the cross-sectional
analyses, who in addition had measurements of CRP concentra-
tion assessed 1991–1993 when they were aged 39–64 years (mean
age 49.2 years). Participants included in any analyses provided
written informed consent and the study complies with the
guidelines of the Declaration of Helsinki.
Clinical Characteristics
Clinical characteristics included age, sex, systolic and diastolic
blood pressure, HDL- and LDL-cholesterol. triglycerides, body
mass index (BMI, weight in kilograms divided by height in meters
squared), smoking, physical activity, socioeconomic position, and
status of diabetes and CHD, all measured in 2003–2004 at mean
age 61 years. Systolic and diastolic blood pressure were measured
twice using the Hawksley random-zero sphygmomanometer with
the participant sitting after a 5-minute rest. The average of these
two measures was recorded. Systolic was the pressure at which the
Korotkoff sound was first heard clearly and diastolic was the
pressure at which the sound disappeared. Blood samples were
collected after either an 8-h fast (participants presenting to the
clinic in the morning) or at least 4 h after a light fat-free breakfast
(participants presenting in the afternoon). Venepuncture of the left
antecubital vein was performed with tourniquet. Blood was
collected into plain and fluoride Sarstedt (Neumbrecht, Germany)
monovettes. Serum for lipid analyses was refrigerated at24uC and
assayed within 72 hours. Cholesterol and triglycerides were
measured with the use of a Cobas Fara centrifugal analyzer
(Roche Diagnostics System, Nutley, NJ). HDL-cholesterol was
measured by precipitating non-HDL cholesterol with dextran
sulfate-magnesium chloride with the use of a centrifuge and
measuring cholesterol in the supernatant fluid. LDL-cholesterol
concentration was calculated using the Friedewald formula.
Weight was measured with all items of clothing removed except
underwear. A Soehnle scale was used to weigh individuals to the
nearest 0.1 kg. Height was measured to the nearest mm using a
stadiometer with the participant in bare-feet, standing completely
erect with the head in the Frankfurt plane. Smoking (ever smoker
vs never smoker) and physical inactivity (sedentary vs not) were
recorded. Socioeconomic position was a dichotomy, clerical vs not,
based on employment grade in 2003–2004 or, if retired, the latest
employment grade.
Diabetes status at mean age 61 was assessed on the basis of 75g
oral glucose tolerance test, use of diabetes medication or self-report
of doctor diagnosis, all measured at mean ages 49, 56 and 61.
Diabetes was defined by 2h glucose$11.1 mmol/L or fasting
glucose$7 mmol/L. Prevalent CHD comprised a history of non-
fatal myocardial infarction or definite angina. Potential prevalent
cases of non-fatal myocardial infarction were ascertained by
questionnaire items on chest pain [55] and the physician’s
diagnosis of a heart attack. The confirmation of myocardial
infarction according to MONICA criteria [56] was based on
electrocardiographic findings, markers of myocardial necrosis and
a history of chest pain in the medical records. The assessment of
angina was based on the participant’s reports of symptoms, with
corroboration in medical records or abnormalities in a resting
electrocardiogram (ECG), an exercise ECG, or a coronary
angiogram.
CRP Polymorphism Genotyping
DNA was extracted from blood samples obtained at baseline
using magnetic beads technology (Geneservice Ltd, Cambridge).
Using validated genotype data (minor allele frequency .5%) from
subjects of European descent from the NHLBI PGA database
(http://pga.mbt.washington.edu/), and the human HapMap
database (http://www.hapmap.org/), we examined the pattern
CRP and CIMT
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of linkage disequilibrium across the CRP gene. We then used the
haplotype LD r2 method to select a set of tagging (t)SNPs capable
of capturing maximum haplotype diversity among subjects of
European descent using the programme TagIT (http://popgen.
biol.ucl.ac.uk/software.html). We genotyped 3 SNPs in the CRP
gene [+1444T.C (rs1130864); +2303G.A (rs1205) and
+4899T.G (rs 3093077)] using the ABI Prism 7900HT Sequence
Detection System for both PCR and allelic discrimination (Applied
Biosystems, Foster City, CA). The SNPs were genotyped using
Assays by Design from Applied Biosystems under standard
conditions. Genotype calling was done manually from the PCR
run component tab. The Hardy Weinberg Equilibrium (HWE)
was tested at each SNP and CRP +2303 and +4899 were found to
be in HWE (x2 p.0.05), but +1444 was not in HWE (p = 0.003).
The +1444 SNP was re-genotyped from 678 samples in a different
laboratory and the results called by a researcher who was blind to
the original results. The mismatch rate was 0.5% suggesting that
lacking HWE for +1444 may be due to random residual
genotyping error, but biological selection bias or other popula-
tional inhomogeneity cannot fully be excluded.
Measurement of C-Reactive Protein
CRP was measured in serum stored at 280uC using a high-
sensitivity immunonephelometric assay in a BN ProSpec nephe-
lometer (Dade Behring, Milton Keynes, UK). Values below the
detection limit (0.154 mg/L) were assigned a value of 0.077 mg/L
(n = 333 (7.1%) in 1991–1993 at mean age 49 and n = 104 (2.0%)
in 2003–2004 at mean age 61). Samples from both study phases
were analyzed at the same time. Intra- and inter-assay coefficients
of variation were 4.7% and 8.3%. To measure short-term
biological variation and laboratory error, a repeated sample was
taken from a subset of 150 participants in 1991–1993 and 533
participants in 2003–2004 (average time between samples 32
(SD = 10.5) and 24 (SD = 11.0) days respectively). Reliability
between samples was assessed with intraclass correlation:
r = 0.83 in 1991–1993 and r = 0.57 in 2003–2004.
Measurement of Carotid Intima-media Thickness
Ultrasound vascular measurements in 2003–2004 were taken in
a temperature controlled (22–26 degrees centigrade), quiet room
using a non-invasive, high- resolution ultrasound system, the Aloka
Prosound 5500 with a 7.5 MHz linear array transducer.
Participants were examined in a supine position, with the head
turned to a 45 degree angle away from the side to be scanned.
CIMT was measured in the right and left common carotid
arteries. Longitudinal images of the common carotid artery,
triggered on the R-wave of the ECG, were magnified and
recorded in DICOM format as a cine loop, on the hard drive of
the ultrasound machine for later analysis. The common CIMT
was measured at its thickest part 1 cm proximal to the bifurcation.
A measurement was taken between the leading edge of the intima
and the media adventitia on 3 separate images on each side using
electronic callipers and the mean of the 6 measures was used for
analysis. Three observers conducted CIMT studies with inter and
intra-observer variability measurements ranging between 2.6%
and 5.8%. The overall coefficient of variation for repeated
measures of CIMT was 4.7% (N = 89).
Data Analysis
Standard Regression Analysis. We used age- and sex-
adjusted least square regression analysis to assess (i) the associa-
tions between potential confounding factors (BMI, smoking,
physical activity and socioeconomic position) and circulating
CRP levels and between potential confounding factors and CIMT;
(ii) the association between circulating CRP levels and CIMT (in a
multivariable model, additional adjustment was made for potential
confounding factors); and (iii) the association of haplotypes (see
below) with circulating CRP levels, potential confounding factors
and CIMT. The haplotype-confounder associations were
undertaken to test our underlying hypothesis that genetic
variants in CRP would not be associated with other risk factors
that affect conventional observational epidemiological
associations.
Haplotype Construction. We constructed haplotypes with
the genetic data analysis program SIMHAP (see http://www.
genepi.com/au/project/simhap, obtained May 2, 2007), using
1000 iterations and a posterior probability .0.95. With this
procedure, only one haplotype pair was constructed for each
participants. The 13 individuals with a haplotype with a frequency
less than 1% were not included in our cohort of 4941 individuals.
Thus, 4 haplotypes of SNPs +1444, +2302 and +4899 (CAT,
CGG, CGT and TGT) remained in the analysis in which genetic
variants were used to determine the association of CRP with
CIMT.
Instrumental Variables Analysis. An instrumental
variables analysis, in which haplotypes in CRP were used as
instrumental variables for the unconfounded and unbiased effect
of CRP on CIMT, was undertaken using two-stage least squares
method [16]. In these analyses we used a model for the haplotype-
CRP association that assumes each of a participant’s two
haplotypes contributes additively to his/her value of CRP, as
done in a previous study that used similar CRP haplotypes as
instruments for the effect of CRP on components of the metabolic
syndrome [20]. We used the F-statistics from the first-stage
regressions to evaluate the strength of the instruments (values
greater than 10 are taken to indicate sufficient strength to ensure
the validity of instrumental variable methods) [39]. Instrumental
variable regression analysis was performed with Stata, version 9.2
(Stata Institute, Texas, USA).
General Analytic Procedures. There was no strong
statistical evidence that any of the associations we examined
differed by sex, which is consistent with previous studies in the field
[22,24]. Therefore all results are presented for women and men
combined. Due to skewness, we logarithmically transformed CRP
in the analyses, we used logs to base 2 so that we could present
associations per doubling of CRP, which are easy to interpret and
consistent with previous studies in this area [20,22]. All analyses
(except haplotype construction and instrumental variable analysis)
were performed with SAS statistical software, version 9.1 (SAS
Institute, Cary, USA).
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